Literature DB >> 28402755

Distribution of FcRn Across Species and Tissues.

Sari Latvala1, Bjoern Jacobsen1, Michael B Otteneder1, Annika Herrmann1, Sven Kronenberg1.   

Abstract

The neonatal Fc receptor (FcRn) is a major histocompatibility complex class I type molecule that binds to, transports, and recycles immunoglobulin G (IgG) and albumin, thereby protecting them from lysosomal degradation. Therefore, besides the knowledge of FcRn affinity, FcRn protein expression is critical in understanding the pharmacokinetic behavior of Fc-containing biotherapeutics such as monoclonal antibodies. The goal of this investigation was to achieve for the first time a comparative assessment of FcRn distribution across a variety of tissues and species. FcRn was mapped in about 20 tissues including placenta from human and the most frequently used species in non-clinical safety testing of monoclonal antibodies (mouse, rat, cynomolgus monkey). In addition, the FcRn expression pattern was characterized in two humanized transgenic mouse lines (Tg32 and Tg276) expressing human FcRn under different promoters, and in the severe combined immunodeficient (SCID) mouse. Consecutive sections were stained with specific markers, namely, anti-CD68 for macrophages and anti-von Willebrand Factor for endothelial cells. Overall, the FcRn expression pattern was comparable across species and tissues with consistent expression of FcRn in endothelial cells and interstitial macrophages, Kupffer cells, alveolar macrophages, enterocytes, and choroid plexus epithelium. The human FcRn transgenic mouse Tg276 showed a different and much more widespread staining pattern of FcRn. In addition, immunodeficiency and lack of IgG in SCID mice had no negative effect on FcRn expression compared with wild-type mice.

Entities:  

Keywords:  FcRn; SCID mouse; cynomolgus monkey; human; humanized transgenic mice Tg32 and Tg276; immunohistochemistry; mouse; neonatal Fc receptor; rat; species comparison

Mesh:

Substances:

Year:  2017        PMID: 28402755      PMCID: PMC5625855          DOI: 10.1369/0022155417705095

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  44 in total

1.  Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung.

Authors:  Masahiro Sakagami; Yadollah Omidi; Lee Campbell; Lana E Kandalaft; Christopher J Morris; Jaleh Barar; Mark Gumbleton
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

2.  Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.

Authors:  Masaru Yoshida; Kanna Kobayashi; Timothy T Kuo; Lynn Bry; Jonathan N Glickman; Steven M Claypool; Arthur Kaser; Takashi Nagaishi; Darren E Higgins; Emiko Mizoguchi; Yoshio Wakatsuki; Derry C Roopenian; Atsushi Mizoguchi; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

3.  The transmission of immunity from mother to young and the catabolism of immunoglobulins.

Authors:  F W Brambell
Journal:  Lancet       Date:  1966-11-19       Impact factor: 79.321

4.  An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta.

Authors:  N E Simister; C M Story; H L Chen; J S Hunt
Journal:  Eur J Immunol       Date:  1996-07       Impact factor: 5.532

5.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

6.  Expression of neonatal Fc receptor in the eye.

Authors:  Michael B Powner; Jenny A G McKenzie; Gregory J Christianson; Derry C Roopenian; Marcus Fruttiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

7.  Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Authors:  Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

8.  Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.

Authors:  V Ghetie; J G Hubbard; J K Kim; M F Tsen; Y Lee; E S Ward
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

9.  The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan.

Authors:  Chaity Chaudhury; Samina Mehnaz; John M Robinson; William L Hayton; Dennis K Pearl; Derry C Roopenian; Clark L Anderson
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

10.  Abundant intracellular IgG in enterocytes and endoderm lacking FcRn.

Authors:  Sudhasri Mohanty; Jonghan Kim; Latha P Ganesan; Gary S Phillips; John M Robinson; Clark L Anderson
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more
  41 in total

1.  The neonatal Fc receptor is a pan-echovirus receptor.

Authors:  Stefanie Morosky; Alexandra I Wells; Kathryn Lemon; Azia S Evans; Sandra Schamus; Christopher J Bakkenist; Carolyn B Coyne
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-11       Impact factor: 11.205

2.  Maternal alloimmune IgG causes anti-glomerular basement membrane disease in perinatal transgenic mice that express human laminin α5.

Authors:  Dale R Abrahamson; Brooke M Steenhard; Larysa Stroganova; Adrian Zelenchuk; Patricia L St John; Margaret G Petroff; Manuel Patarroyo; Dorin Bogdan Borza
Journal:  Kidney Int       Date:  2019-07-10       Impact factor: 10.612

3.  Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.

Authors:  Wolfgang F Richter; Gregory J Christianson; Nicolas Frances; Hans Peter Grimm; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2018-05-09       Impact factor: 5.857

4.  Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.

Authors:  Shihao Hu; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-06-04       Impact factor: 2.745

5.  Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography-Multiple Reaction Monitoring-based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models.

Authors:  Xiazi Qiu; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2020-07-28       Impact factor: 3.922

6.  Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.

Authors:  Armin Sepp; Guy Meno-Tetang; Andrew Weber; Andrew Sanderson; Oliver Schon; Alienor Berges
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-11       Impact factor: 2.745

7.  A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  Eur J Pharm Sci       Date:  2019-08-05       Impact factor: 4.384

8.  Depletion of the apical endosome in response to viruses and bacterial toxins provides cell-autonomous host defense at mucosal surfaces.

Authors:  Keiko Maeda; Nicholas C Zachos; Megan H Orzalli; Stefanie S Schmieder; Denis Chang; Katlynn Bugda Gwilt; Michele Doucet; Nicholas W Baetz; Sun Lee; Sue E Crawford; Mary K Estes; Jonathan C Kagan; Jerrold R Turner; Wayne I Lencer
Journal:  Cell Host Microbe       Date:  2022-02-09       Impact factor: 21.023

Review 9.  Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias.

Authors:  Sarah L Wyckoff; Krystalyn E Hudson
Journal:  Transfusion       Date:  2021-03-02       Impact factor: 3.157

10.  Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.

Authors:  Paul R V Malik; Abdullah Hamadeh; Andrea N Edginton
Journal:  Pharm Res       Date:  2022-02-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.